

insulin detemir (Levemir ®)

(No. 138/04)

Novo Nordisk Ltd

Product Update

5 November 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Insulin detemir is accepted for restricted use in Scotland in the treatment of children and adolescents with diabetes mellitus. The licence has been extended to include these patient groups and the restriction reflects similar advice from the Scottish Medicines Consortium (August 2004) when insulin detemir was reviewed as a new product for adult patients only.

Advice context:

No part of this advice may be used without the whole of the advice quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 29 October, 2004.

**Chairman
Scottish Medicines Consortium**